pharma · Age-related Macular Degeneration · Neovascular Age-related Macular Degeneration · OTLK
Outlook Therapeutics NL
Outlook Therapeutics NL B. V.
Outlook Therapeutics NL patent portfolio — 2 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Cranbury, USA
- Founded
- 2011
- Employees
- 59
- Programs
- 2
- Drugs
- 3
- Patents
- 2
Outlook Therapeutics NL patents
2 pharmaceutical patents indexed for Outlook Therapeutics NL. 0 expire within 24 months.
Outlook Therapeutics NL has 2 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
Frequently asked questions
How many patents does Outlook Therapeutics NL have?
2 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Outlook Therapeutics NL patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.